CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...